Skip to main
  1. Stocks
  2. Johnson & Johnson
  3. Forecast
JNJ

JNJ Stock Forecast & Price Target

JNJ Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 32%
Buy 32%
Hold 37%
Sell 0%
Strong Sell 0%

Bulls say

Johnson & Johnson is attractive because the 2023 consumer separation sharpened its focus on higher-return Innovative Medicines and MedTech, improving productivity and supporting stronger margins. Its core drug franchises in immunology, oncology, and neurology are showing durable momentum, with Tremfya, Darzalex, Icotyde, and Spravato offsetting pressure from certain headwinds and sustaining volume growth. The company also has a robust pipeline and a broad MedTech platform, with 12 platforms above $1B in sales and leadership in 11 of them, while just over half of revenue comes from the United States.

Bears say

Johnson & Johnson is vulnerable to slower organic revenue growth as loss of exclusivity pressures key drugs such as Stelara, with biosimilar erosion already in its year two and full-year erosion guidance of about 60% still intact. Its innovative medicine pipeline may not offset that drag if products like Tremfya, Carvykti, Rybrevant, the TARIS platform, nipocalimab, and milvexian fail to gain traction, while MedTech faces persistent competitive headwinds in electrophysiology and pulsed field ablation that could delay a 2H26 recovery. Added uncertainty from M&A integration risk, weaker P&L discipline, U.S. drug pricing reform, and ongoing talc litigation supports a cautious view on earnings durability and valuation.

JNJ has been analyzed by 19 analysts, with a consensus rating of Buy. 32% of analysts recommend a Strong Buy, 32% recommend Buy, 37% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Johnson & Johnson and is not a guaranteed prediction by Public.com or investment advice.

JNJ Analyst Forecast & Price Prediction

Get the latest JNJ stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in JNJ

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Johnson & Johnson (JNJ) Forecast

Analysts have given JNJ a Buy based on their latest research and market trends.

According to 19 analysts, JNJ has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $270.11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $270.11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Johnson & Johnson (JNJ)


JNJ Analyst Forecast & Price Prediction

Get the latest JNJ stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in JNJ

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover JNJ stock data and trends